Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions. The bone graft incorporates rhBMP-2 and is designed to enhance ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Many types of solid tumors and tumor endothelia express CD95L.Based on research from a team at the German Cancer Research Center, Apogenix has been developing APG101, an Fc-fusion protein that ...

Amphix Bio has received a breakthrough device designation from the US Food and Drug Administration (FDA ... spinal fusion surgeries without relying on donor tissue or recombinant proteins ...

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat neurotrophic ... Tumours with NTRK gene fusion produce an altered TRK ...

Furthermore, IBI363 has received two fast track designations (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment ... bispecific antibody fusion protein) IBI363 is a first ...

"The full approval of VITRAKVI by the FDA is a welcome step forward, solidifying its place as a treatment option for patients with NTRK gene fusion-positive cancers," said Andrea Ferris ...

The drug is a fusion protein comprising the human interleukin (IL)-1 type 1 receptor (extracellular domain and accessory protein) and the Fc portion of human IgG1. Regeneron's drug is the only ...

With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion. "The FDA has cleared the Catamaran SI Joint Fusion System ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

Furthermore, IBI363 has received two fast track designations (FTD) from the US Food and Drug Administration (FDA), for the treatment of squamous ... It is a PD-1/IL-2 bispecific antibody fusion ...